Report Description
A recent market
intelligence report that is published by Data Insights Partner on the global Biosimilar
Testing Service makes an offering of in-depth analysis of segments and
sub-segments in the regional and international Biosimilar Testing Service Market.
The research also emphasizes on the impact of restraints, drivers, and macro
indicators on the regional and global Biosimilar Testing Service Market over
the short as well as long period of time. A detailed presentation of forecast, trends,
and dollar values of global Biosimilar Testing Service Market is offered. In
accordance with the report, the global Biosimilar Testing Service Market is
projected to expand at a CAGR of 27.20 % over the period of forecast.
Market Insight, Drivers, Restraints&
Opportunity of the Market:
A biosimilar is
a medical product that is similar to another already approved biological
medicine. Biosimilar are approved according to the same standards of pharmaceuticals
quality, purity, safety, potency and effectiveness that is available in a
biological medicine. Biosimilar can be manufactured when the original product’s
patent expires.
There has been a
tremendous growth in the demand for biosimilar products. High investment on
research & development by manufacturers is the major driver for global Biosimilar
Testing Service Market. Lower cost of biosimilar than the original drug and
market opportunities in untapped emerging nations such as China, India &
Brazil will further boost the growth of this market. The demand for biosimilar
is increasing as the patent expiry date for many bestseller biologics
approaches. In 2018-2023 period alone, there were patent exclusivity expire for
17 biologics in Europe. Undeniably, this opens up a huge market opportunity for
Biosimilar Testing Service market.
However, the major restraining
factor for the global Biosimilar
Testing Service market is the expensive development procedure. Also, there is a
shortage of skilled professional which could further hinder the growth of this
market. Also, the current demonstration of total interchangeability from the
original biological medicine to biosimilar products is still quite low and this
will further hamper the growth of this market.
The Asia Pacific region, will occupy the most
market share, especially in countries like China, India and countries in Southeast
Asian region. United States in North American region will also play an
important role in this market over the forecast period.
Research &
Development scientists are continually developing new off-the-shelf methods to
support biosimilar characterization and comparability.
Segment Covered:
This market
intelligence report on the global Biosimilar Testing Service Market encompasses
market segments based on clinical assays, comparability testing, application,
molecule, indication and country/regions.
In terms of clinical assays, the global Biosimilar
Testing Service Market
is segregated into
§ PK assays
§ Pharmacokinetic Assay
§ Tiered Immunogenicity testing
§ NAB assays
§ Others
By comparability testing, the global Biosimilar
Testing Service Market
is also classified into,
§ Effector Binding
ü FcRI (CD64)
ü FcRII (CD32a)
ü FcRIII (CD16a)
ü FcRn
§ ELISA
§ Kinetic Binding Assays
§ ADCC & CDC Cell Based Assays
§ Others
In terms of application, the global
Biosimilar Testing Service
Market is segregated into
§ Hospitals
§ Pharmaceutical Companies
§ Others
In terms of molecule, the global Biosimilar
Testing Service
Market is segregated into
§ Infliximab
§ Insuline Glargine
§ Epoetin Alfa
§ Etanercept
§ Filgrastim
§ Somatropin
§ Rituximab
§ Follitropin Alfa
§ Others
In terms of indication, the global Biosimilar
Testing Service
Market is segregated into
§ Autoimmune diseases
§ Oncology
§ Diabetes
§ Blood Disorder
§ Growth Deficiency
§ Female infertility
§ Others
By country/region, the global Biosimilar Testing Service Market has been divided into
§ North America (the U.S., Canada),
§ Latin America (Brazil, Mexico, Argentina and other
countries),
§ Europe (Germany, France, the U.K., Spain, Italy, Russia,
and other countries),
§ Asia Pacific (India, Japan, China, Australia and New Zealand
and other countries),
§ Middle East and Africa (GCC, South Africa, Israel and
Other countries).
Profiling of Market
Players:
This business
intelligence report offers profiling of reputed companies that are operating in
the market. Companies such as
§ Eurofins Scientific
§ SGA S.A
§ Charles River Laboratories
§ International Inc.
§ Pharmaceuticals Product Development
§ Exova Group PLC
§ Source Bioscience PLC
§ Intertek Group PLC
§ Medistri SA
§ Pace Analytical Services Inc.
§ Allergan PLC.
§ Bioton S.A
§ Cinnagen
§ Emcure Pharmaceuticals
§ LG Life Sciences
§ Neuclone
§ Sigma – Aldrich Co. LLC and many more
Others players have
been profiled into detail so as to offer a glimpse of the market leaders.
Moreover, parameters such as Biosimilar Testing Service related investment & spending and developments by
major players of the market are tracked in this global report.
Report Highlights:
In-depth
analysis of the micro and macro indicators, market trends, and forecasts of
demand is offered by this business intelligence report. Furthermore, the report
offers a vivid picture of the factors that are steering and restraining the
growth of this market across all geographical segments. In addition to that, Growth
Matrix analysis is also provided in the report so as to share insight of the
investment areas that new or existing market players can take into consideration.
Various analytical tools such as DRO analysis, Porter's five forces analysis
has been used in this report to present a clear picture of the market. The
study focuses on the present market trends and provides market forecast from
the year 2020-2028. Emerging trends that would shape the market demand in the
years to come have been highlighted in this report. A competitive analysis in
each of the geographical segments gives an insight into market share of the
global players.
Salient Features:
Ø
This study offers
comprehensive yet detailed analysis of the Biosimilar Testing Service Market, size of the market (US$ Mn), and Compound Annual Growth
Rate (CAGR (%)) for the period of forecast: 2020 – 2028, taking into account
2019 as the base year
Ø
It explains upcoming
revenue opportunities across various market segments and attractive matrix of
investment proposition for the said market
Ø
This market
intelligence report also offers pivotal insights about various market opportunities,
restraints, drivers, launch of new products, competitive market strategies of
leading market players, emerging market trends, and regional outlook
Ø
Profiling of
key market players in the world Biosimilar
Testing Service Market
is done by taking into account various parameters
such as company strategies, distribution strategies, product portfolio, financial
performance, key developments, geographical presence, and company overview
Ø
Leading market
players covered this report comprise names such as Eurofins Scientific, SGA
S.A., Charles River Laboratories, International Inc., Pharmaceuticals Product
Development, Exova Group PLC, Source Bioscience PLC, Intertek Group PLC,
Medistri SA, Pace Analyical Services Inc., Allergan PLC., Bioton SA., Cinnagen,
Emcure Pharmaceuticals, LG Life Sciences, Neuclone and Sigma-Aldrich Co. Ltd. and many more.
Ø
The data of
this report would allow management authorities and marketers of companies alike
to take informed decision when it comes to launch of products, government
initiatives, marketing tactics and expansion, and technical up gradation
Ø
The world
market for Biosimilar
Testing Service Market
caters to the needs of various stakeholders
pertaining to this industry, namely suppliers, manufacturers, investors, and
distributors for Biosimilar
Testing Service Market. The research also caters to the rising needs of consulting
and research firms, financial analysts, and new market entrants
Ø
Research
methodologies that have been adopted for the purpose of this study have been
clearly elaborated so as to facilitate better understanding of the reports
Ø
Reports have
been made based on the guidelines as mandated by General Data Protection
Regulation
Ø
Ample number
of examples and case studies have been taken into consideration before coming
to a conclusion
Reasons to buy:
v
Identify
opportunities and plan strategies by having a strong understanding of the
investment opportunities in the Biosimilar Testing Service Market
v
Identification
of key factors driving investment opportunities in the Biosimilar Testing
Service Market
v
Facilitate
decision-making based on strong historic and forecast data
v
Position
yourself to gain the maximum advantage of the industry’s growth potential
v
Develop
strategies based on the latest regulatory events
v
Identify key
partners and business development avenues
v
Respond to your
competitors’ business structure, strategy and prospects
v
Identify key
strengths and weaknesses of important market participants